
**Cardiovascular implants — Cardiac
valve prostheses —**

**Part 2:
Surgically implanted heart valve
substitutes**

Implants cardiovasculaires — Prothèses valvulaires —

Partie 2: Prothèse valvulaires implantées chirurgicalement





COPYRIGHT PROTECTED DOCUMENT

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

	Page
Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Abbreviations	3
5 Fundamental requirements	4
6 Device description	4
6.1 General	4
6.2 Intended use	4
6.3 Design inputs	4
6.3.1 Operational specifications	4
6.3.2 Performance specifications	4
6.3.3 Packaging, labelling, and sterilization	5
6.4 Design outputs	5
6.5 Design transfer (manufacturing verification/validation)	5
6.6 Risk management	6
7 Design verification and validation	6
7.1 General requirements	6
7.2 <i>In vitro</i> assessment	6
7.2.1 General	6
7.2.2 Test conditions, sample selection, and reporting requirements	6
7.2.3 Material property assessment	6
7.2.4 Hydrodynamic performance assessment	6
7.2.5 Structural performance assessment	7
7.2.6 Design- or procedure-specific testing	8
7.2.7 Device MRI compatibility	8
7.2.8 Simulated use	8
7.2.9 Human factors/usability assessment	8
7.2.10 Implant thrombogenic and haemolytic potential assessment	8
7.3 Preclinical <i>in vivo</i> evaluation	8
7.3.1 General	8
7.3.2 Overall requirements	8
7.3.3 Methods	9
7.3.4 Test report	10
7.4 Clinical investigations	11
7.4.1 General	11
7.4.2 Study considerations	12
7.4.3 Study endpoints	13
7.4.4 Ethical considerations	14
7.4.5 Pivotal studies: Distribution of subjects and investigators	14
7.4.6 Statistical considerations including sample size and duration	15
7.4.7 Patient selection criteria	16
7.4.8 Valve thrombosis prevention	17
7.4.9 Clinical data requirements	17
Annex A (informative) Surgical heart valve substitute hazard analysis example	22
Annex B (informative) <i>In vitro</i> procedures for testing unstented or similar valves in compliant chambers	24
Annex C (informative) Preclinical <i>in vivo</i> evaluation	26
Annex D (informative) Description of the surgical heart valve substitute and system	29

Annex E (informative) Examples of components of some surgical heart valve substitutes and systems	31
Annex F (informative) Guidelines for verification of hydrodynamic performance — Pulsatile flow testing	37
Annex G (informative) Examples of design specific testing	41
Annex H (informative) Fatigue assessment	43
Annex I (normative) Methods of evaluating clinical data against objective performance criteria	45
Annex J (normative) Adverse event classification during clinical investigation	46
Bibliography	51

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 285, *Non-active surgical implants*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 5840-2:2015), which has been technically revised.

The main changes compared to the previous edition are as follows: the engineering and clinical requirements in the ISO 5840 series have been updated to current specifications and integrated and harmonized across all of its parts.

A list of all parts in the ISO 5840 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

This document has been prepared for surgical heart valve substitutes with emphasis on providing guidance for *in vitro* testing, preclinical *in vivo* and clinical evaluations, reporting of all *in vitro*, preclinical *in vivo*, and clinical evaluations and labelling and packaging of the device. This process is intended to clarify the required procedures prior to market release and to enable prompt identification and management of any subsequent issues.

This document is used in conjunction with ISO 5840-1 and ISO 5840-3.

Cardiovascular implants — Cardiac valve prostheses —

Part 2: Surgically implanted heart valve substitutes

1 Scope

This document is applicable to heart valve substitutes intended for implantation in human hearts, generally requiring cardiopulmonary bypass and generally with direct visualization. See [Annex E](#) for examples of surgical heart valve substitutes and their components.

This document is applicable to both newly developed and modified surgical heart valve substitutes and to the accessory devices, packaging, and labelling required for their implantation and for determining the appropriate size of the surgical heart valve substitute to be implanted.

This document establishes an approach for verifying/validating the design and manufacture of a surgical heart valve substitute through risk management. The selection of appropriate qualification tests and methods are derived from the risk assessment. The tests can include those to assess the physical, chemical, biological, and mechanical properties of surgical heart valve substitutes and of their materials and components. The tests can also include those for pre-clinical *in vivo* evaluation and clinical evaluation of the finished surgical heart valve substitute.

This document defines operational conditions and performance requirements for surgical heart valve substitutes where adequate scientific and/or clinical evidence exists for their justification.

For some heart valve substitutes (e.g. sutureless), the requirements of both this document and ISO 5840-3:2021 can be relevant and are considered as applicable to the specific device design and are based on the results of the risk analysis.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 5840-1:2021, *Cardiovascular implants — Cardiac valve prostheses — Part 1: General requirements*

ISO 5840-3, *Cardiovascular implants — Cardiac valve prostheses — Part 3: Heart valve substitutes implanted by transcatheter techniques*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

ISO 14630, *Non-active surgical implants — General requirements*

ISO 16061, *Instrumentation for use in association with non-active surgical implants — General requirements*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 5840-1:2021 and the following apply.